PT880362E - Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4 - Google Patents

Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4

Info

Publication number
PT880362E
PT880362E PT97905663T PT97905663T PT880362E PT 880362 E PT880362 E PT 880362E PT 97905663 T PT97905663 T PT 97905663T PT 97905663 T PT97905663 T PT 97905663T PT 880362 E PT880362 E PT 880362E
Authority
PT
Portugal
Prior art keywords
alkyl
arylamino
aralkylaminoalkyl
arylaminosulfonyl
arylaminoalkyl
Prior art date
Application number
PT97905663T
Other languages
English (en)
Portuguese (pt)
Inventor
Peter C Isakson
Susan A Gregory
Anderson Gary
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of PT880362E publication Critical patent/PT880362E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PT97905663T 1996-02-13 1997-02-11 Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4 PT880362E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60058096A 1996-02-13 1996-02-13

Publications (1)

Publication Number Publication Date
PT880362E true PT880362E (pt) 2005-10-31

Family

ID=24404169

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97905663T PT880362E (pt) 1996-02-13 1997-02-11 Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4

Country Status (10)

Country Link
US (3) US6172096B1 (enExample)
EP (2) EP0880362B1 (enExample)
JP (1) JP2000505445A (enExample)
AT (1) ATE296114T1 (enExample)
AU (1) AU2250097A (enExample)
CA (1) CA2246356A1 (enExample)
DE (1) DE69733338T2 (enExample)
ES (1) ES2243978T3 (enExample)
PT (1) PT880362E (enExample)
WO (1) WO1997029775A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2246336A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
JP2000504723A (ja) 1996-02-13 2000-04-18 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ―２阻害剤および５―リポキシゲナーゼ阻害剤投与の免疫抑制効果
ATE296114T1 (de) * 1996-02-13 2005-06-15 Searle & Co Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten
CA2313049A1 (en) * 1997-12-17 1999-06-24 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
US7041694B1 (en) * 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
US6767890B1 (en) * 1998-11-18 2004-07-27 Coastside Bio Resources Peptides having anti-cancer and anti-inflammatory activity
EP1282423A2 (en) * 2000-05-11 2003-02-12 Oklahoma Medical Research Foundation Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with ns398 or pdtc
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
CA2484989A1 (en) * 2002-05-02 2003-11-27 The Washington University Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
RS20050390A (sr) * 2002-11-26 2008-04-04 Boehringer Ingelheim Pharma Gmbh. & Co.Kg., Farmaceutska kompozicija koja obuhvata ltb4 antagonist i koks-2 inhibitor ili kombinovani koks1/2 inhibitor
US20040242676A1 (en) * 2003-05-30 2004-12-02 Alessi Thomas R. Method of mitigating the adverse effects of IL-2
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CN102144961A (zh) 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
WO2005102388A1 (ja) * 2004-04-26 2005-11-03 Ono Pharmaceutical Co., Ltd. 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
WO2006030753A1 (ja) * 2004-09-13 2006-03-23 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP1853259A1 (en) 2005-02-09 2007-11-14 Macusight, Inc. Formulations for ocular treatment
WO2006113261A2 (en) * 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
AU2006270041B2 (en) 2005-07-18 2011-08-18 Minu, Llc Enhanced ocular neuroprotection/neurostimulation
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
US20090291883A1 (en) * 2006-07-14 2009-11-26 Boston Medical Center Corporation Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat disease
US20090017140A1 (en) * 2007-07-09 2009-01-15 Peter Koepke Maytenus abenfolia extract and methods of extracting and using such extract
US20090035395A1 (en) * 2007-08-01 2009-02-05 Peter Koepke Spondias mombin l. extract and methods of extracting and using such extract
US7879369B2 (en) * 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196839A (ja) 1983-04-21 1984-11-08 Sankyo Co Ltd フエニル酢酸誘導体
US4923891A (en) 1987-09-24 1990-05-08 G. D. Searle & Co. Leukotriene LTD4 and LTB4 antagonists
US4970234A (en) 1987-12-08 1990-11-13 G. D. Searle & Co. Furyl, phenylene, and thienyl leukotriene B4 analogues
US4889935A (en) 1987-12-18 1989-12-26 American Home Products Corporation Aminoguanidine derivatives
US4871771A (en) 1988-02-04 1989-10-03 Smithkline Beckman Corporation Leukotriene antagonists
US5384318A (en) * 1989-06-22 1995-01-24 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
US5256686A (en) 1989-06-27 1993-10-26 Ono Pharmaceutical Co., Ltd. Phenylalkan(en)oic acid
US5212198A (en) 1990-05-10 1993-05-18 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
US5121198A (en) * 1990-06-28 1992-06-09 Eastman Kodak Company Method of setting the contrast of a color video picture in a computer controlled photographic film analyzing system
US5124350A (en) 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JPH0439864U (enExample) * 1990-07-30 1992-04-03
US5232948A (en) 1990-09-10 1993-08-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted monocyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
IE913655A1 (en) 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
US5246965A (en) * 1991-06-11 1993-09-21 Ciba-Geigy Arylethers, their manufacture and methods of treatment
US5272178A (en) 1991-11-18 1993-12-21 G. D. Searle & Co. Compounds of cyclic phenolic thioethers which are useful in stimulating and inhibiting superoxide generation
DE4141746A1 (de) * 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
GB9215921D0 (en) 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
DE4228201A1 (de) * 1992-08-25 1994-03-03 Schering Ag Neue Leukotrien-B¶4¶-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
DE9422447U1 (de) 1993-01-15 2002-10-17 G.D. Searle LLC, Chicago, Ill. 3,4-Diarylthiophene und Analoga davon, sowie deren Verwendung als entzündungshemmende Mittel
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5380740A (en) 1993-04-28 1995-01-10 G. D. Searle & Co. Anti-inflammatory compounds, compositions and method of use thereof
AU6718494A (en) 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5412151A (en) 1993-10-22 1995-05-02 Eastman Chemical Company Thermosetting coating compositions
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
KR100263817B1 (ko) * 1993-11-30 2000-08-16 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
KR100297091B1 (ko) 1993-12-09 2001-11-05 고래마츠 교지 크롬-프리벽돌
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
JPH11507669A (ja) * 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターとロイコトリエンｂ▲下４▼受容体アンタゴニストの組合せによる炎症と炎症関連疾患の治療
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
ATE296114T1 (de) * 1996-02-13 2005-06-15 Searle & Co Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten

Also Published As

Publication number Publication date
AU2250097A (en) 1997-09-02
ES2243978T3 (es) 2005-12-01
US7141599B2 (en) 2006-11-28
US20040106668A1 (en) 2004-06-03
JP2000505445A (ja) 2000-05-09
DE69733338T2 (de) 2006-03-16
EP0880362A1 (en) 1998-12-02
DE69733338D1 (de) 2005-06-30
US6617345B1 (en) 2003-09-09
CA2246356A1 (en) 1997-08-21
WO1997029775A1 (en) 1997-08-21
EP0880362B1 (en) 2005-05-25
US6172096B1 (en) 2001-01-09
EP1640003A2 (en) 2006-03-29
ATE296114T1 (de) 2005-06-15

Similar Documents

Publication Publication Date Title
PT880362E (pt) Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4
CA2249009A1 (en) Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
NZ509755A (en) Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia
US20040131670A1 (en) Pellicle-resistant gelatin capsule
ZA200307630B (en) Reconstitutable parenteral composition containing a cox-2-inhibitor.
RU99110192A (ru) Способ применения ингибиторов циклооксигеназы-2 для лечения и профилактики неоплазии
ES2271269T3 (es) Utilizacion de inhibidores de cox-2 para el tratamiento de la esquizofrenia o de los trastornos de tic.
US20040235803A1 (en) Dispersible formulation of an anti-inflammatory agent
RU2004121147A (ru) Применение ингибиторов сох-2 в сочетании с противовирусными агентами для лечения инфекции вируса папилломы
JP2006520778A (ja) 乳房炎及び耳障害を治療するための分散性医薬組成物
WO2005009436A1 (en) Dispersible formulation of an anti-inflammatory agent
JP2005501850A5 (enExample)
JP2005507871A5 (enExample)
US20040105885A1 (en) Gelatin capsule exhibiting reduced cross-linking
AR038199A1 (es) Terapia combinada para el tratamiento de infecciones bacterianas
JP2005501083A5 (enExample)
EP1526846A2 (en) Gelatin capsule exhibiting reduced cross-linking
AR020306A1 (es) Composicion terapeutica y su uso como inhibidora de la ciclooxigenasa-2 en la prevencion de alteraciones cardiovasculares.
JP2001521889A5 (enExample)
WO2015004505A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
WO2005009472A2 (en) Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
BR112022019449A2 (pt) Composição com melhor aceitação voluntária
Lenta The purposes of torture
Altug The Cyprus Question
Orzell A" Favorable Interval": The Polish Insurrection in Civil War Diplomacy, 1863